Stay updated on IPI-145 Plus FCR in CLL Clinical Trial
Sign up to get notified when there's something new on the IPI-145 Plus FCR in CLL Clinical Trial page.

Latest updates to the IPI-145 Plus FCR in CLL Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a dedicated Locations section with Massachusetts listed as a study site, and updated the page revision to v3.3.3. The old 'Massachusetts Locations' label was removed and the 'HHS Vulnerability Disclosure' footer link was also removed.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe revision label on the page footer changed from v3.3.1 to v3.3.2.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page now shows Revision: v3.3.1, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedRemoved the government funding lapse and NIH operating status notice from the page.SummaryDifference0.4%

- Check65 days agoChange DetectedUpdates appear to be minor UI/formatting adjustments to the Study Details page and do not modify core study information (eligibility criteria, outcomes, or trial status). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check94 days agoChange DetectedUpdate to v3.2.0 with a government-operating status notice; removal of a specific genetic disease resource (B-cell CLL).SummaryDifference4%

Stay in the know with updates to IPI-145 Plus FCR in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IPI-145 Plus FCR in CLL Clinical Trial page.